AIM: To analyze the effect of Conbercept for exudative age-related macular degeneration(ARMD).

METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0.5mL(0.5mg)and followed up for 3mo. The best corrected visual acuity(BCVA)and central macular thickness(CMT)before and 1wk, 1 and 3mo after treatment were observed.

RESULTS: The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0.9±1.4, 0.7±1.2, 0.5±1.1 and 0.4±0.9. BCVA after treatment were different at different time(F=49.12, P<0.001); BCVA at 1wk and 1mo after treatment were not different compared with before treatment(P>0.05); that at 3mo were significantly different compared with before(P<0.05). There were 19 eyes with improved BCVA at 3mo after treatment, unchanged in 2 eyes. CMT before and at 1wk, 1 and 3mo were 404.25±68.76, 354.25±43.12, 271.75±32.30, 218.30±24.70μm. CMT at different time were significantly different(F=2 487.45, P<0.001); CMT at 1wk, 1 and 3mo were different compared with before treatment(P<0.001). There were no severe complications found.

CONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.